A small-molecule inhibitor of lectin-like oxidized LDL receptor-1 acts by stabilizing an inactive receptor tetramer state

Gisela Schnapp(Boehringer Ingelheim (Germany)), Dennis Fiegen(Boehringer Ingelheim (Germany)), Klaus Klinder(Heidelberg University), Ralf Heilker(Boehringer Ingelheim (Germany)), François Debaene, Frank Büttner(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Iain Lingard(Boehringer Ingelheim (Germany)), Sandra Handschuh(Boehringer Ingelheim (Germany)), Heike Neubauer(Boehringer Ingelheim (Germany)), Michael W. Wolff(University of Iowa), Rainer Walter(Boehringer Ingelheim (Germany)), Jürgen Prestle(Boehringer Ingelheim (Germany)), Markus Zeeb(Boehringer Ingelheim (Germany))
Communications Chemistry
June 10, 2020
10.1038/s42004-020-0321-2
Cited by 22

Related Papers

A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285